Product Description
Bryophyllum pinnatum (syn. Kalanchoe pinnata) is a succulent perennial plant native to Madagascar that was introduced in anthroposophic medicine in the early 20th century (Sourced from: https://pubmed.ncbi.nlm.nih.gov/27220081/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Brazil | France | Germany | Switzerland
Approved Indications: None
Known Adverse Events: None
Company: HELIXOR Heilmittel &KG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Lymphoma|Leukemia|Adie Syndrome|Inflammation|Leg Ulcer|Wound Infection|Hypertension|Nose Cancer|Skin Ulcer|Obstetric Labor, Premature|Depressive Disorder|Overactive Bladder|Skin Cancer|Restless Legs Syndrome|Bladder Cancer|Nocturia|Contraception
Phase 3: Overactive Bladder|Urinary Incontinence, Urge|Enuresis|Other
Phase 2: Overactive Bladder|Obstetric Labor, Premature
Phase 1: Nephrolithiasis|Kidney Calculi
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04480658 |
NCT04480658 | N/A |
Completed |
Nocturia |
2021-02-18 |
2022-01-20 |
Primary Endpoints |
|
NCT06987084 |
NCT06987084 | P1 |
Enrolling by invitation |
Kidney Calculi|Nephrolithiasis |
2025-12-31 |
2025-05-24 |
Primary Endpoints|Treatments |
|
NCT05110599 |
BASEC-Nr. 2021-00941 | P2 |
Terminated |
Obstetric Labor, Premature |
2023-08-25 |
2023-12-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT01127126 |
NCT01127126 | P2 |
Completed |
Overactive Bladder |
2012-01-01 |
2019-03-19 |
Treatments |
|
NCT02129816 |
BryoSoliP | P3 |
Terminated |
Overactive Bladder|Enuresis|Urinary Incontinence, Urge |
2016-04-20 |
2019-03-20 |
Treatments |
|
NCT00391339 |
CI-C-64-Wel-06 | P3 |
Unknown status |
Other |
None |
2019-03-21 |
Treatments |
|
NCT06908044 |
KEK-2024-01549 | P4 |
Active, not recruiting |
Inflammation|Nocturia|Contraception|Hypertension|Overactive Bladder |
2028-06-30 |
2025-04-04 |
Primary Endpoints|Treatments |
|
NCT04825171 |
Bryo-KLA-02 | P4 |
Recruiting |
Restless Legs Syndrome|Nose Cancer|Skin Ulcer|Leg Ulcer|Inflammation|Depressive Disorder|Wound Infection|Bladder Cancer|Skin Cancer|Overactive Bladder|Hypertension|Adie Syndrome |
2022-12-31 |
2022-09-08 |
Primary Endpoints |
|
2004-002711-83 |
anthroposophic supportive medicine | P4 |
Completed |
Leukemia|Lymphoma |
2013-11-30 |
2022-03-12 |
Treatments |
|
NCT00163579 |
BS-2004-UFK-1 | P4 |
Completed |
Obstetric Labor, Premature |
2009-07-01 |
2019-04-05 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |